SELLAS Life Sciences market cap SLS
Share price times shares outstanding: what the whole company sells for, since 2011.
- Today, Nov 2, 2026
- $1.7B
- Highest close in our data
- $3.1B
- Aug 2026
SELLAS Life Sciences is worth $1.7B at the close on Nov 2, 2026, at $8.55 a share.
That is up 931% over the last year and up 1062% over five years.
Its highest close in our data was $3.1B in Aug 2026.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $1.7B | $492.9M | $3.1B | +322% |
| 2025 | $408.8M | $67M | $408.8M | +493% |
| 2024 | $69M | $16.2M | $92.9M | +103% |
| 2023 | $34M | $26.5M | $79.5M | −30% |
| 2022 | $48.6M | $39.3M | $112M | −45% |
| 2021 | $87.8M | $56.4M | $196.4M | +60% |
| 2020 | $55M | $10.1M | $79.2M | +154% |
| 2019 | $21.7M | $2.8M | $36.2M | −25% |
| 2018 | $28.9M | $5.3M | $39.4M | +143% |
| 2017 | $11.9M | $6.4M | $24.5M | −44% |
| 2016 | $21.1M | $21.1M | $403.7M | −91% |
| 2015 | $238M | $180.5M | $360.6M | +28% |
| 2014 | $185.8M | $185.8M | $736.7M | −59% |
| 2013 | $451.5M | $116.3M | $466.2M | +345% |
| 2012 | $101.4M | $24.5M | $149.8M | +402% |
| 2011 | $20.2M | $16.8M | $47M | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest SELLAS Life Sciences' size, closest first, today.
| Company | Market cap |
|---|---|
| SLSSELLAS Life Sciences | $1.7B |
| ANIPANI Pharmaceuticals | $1.6B |
| PAHCPhibro Animal Health | $1.6B |
| PCRXPacira BioSciences | $1.5B |
| ANABAnaptysbio | $1.4B |
| HRMYHarmony Biosciences | $2.2B |
| OMEROmeros | $1.3B |
| PBHPrestige Consumer Healthcare | $2.4B |
| AMPHAmphastar Pharmaceuticals | $1.1B |
| NRIXNurix Therapeutics | $2.8B |
| OGNOrganon | $3.6B |
| Peer median | $1.6B |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on SELLAS Life Sciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.